Climb Bio Inc. Ordinary Shares CLYM 深 滬
已收盤 12-24 16:00:00 美东时间
4.85
+0.250
+5.43%
華盛通- 最 高4.96
- 今 開4.59
- 成交量 32.30万股
- 最 低 4.50
- 昨 收 4.60
- 總市值 3.31亿
- 52周最高 5.048
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 1.05
- 委 比 -72.41%
- 總股本 6818.44万
- 歷史最高 29.69
- 量 比 0.18
- 振 幅 10.00%
- 歷史最低 1.05
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $11
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $9 to $11.
12-18 20:00
美股牛股 | B Riley金融大涨超53%，补交逾期第二季度报告，该季度实现扭亏为盈；Rezolve涨28%
B Riley金融大涨超53%，补交逾期第二季度报告，该季度实现扭亏为盈；Rezolve涨28%，预计年度经常性收入突破2亿美元，大幅超越此前目标>>
12-17 18:50
美股牛股 | KYTX大涨超23%，Miv-cel临床试验取得积极成果；以星航运涨近9%，获瑞士航运集团收购要约
KYTX大涨超23%，Miv-cel临床试验取得积极成果；IMNM涨近16%，实验性药物晚期临床试验达主要终点；以星航运涨近9%，获瑞士航运集团收购要约>>
12-16 19:53
Climb Bio Q3 EPS $(0.19) Misses $(0.14) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) by 31.94 percent. This is a 46.15 percent decrease over losses of $(0.13) per share from the
11-06 20:28
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
Climb Bio appointed Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy. Their expertise will support the company's clinical development and operational efficiency. Villa brings over two decades of experience in biopharmaceutical development, while Jones has a proven track record in building high-performing teams. The company granted inducement equity awards to both exe...
10-21 11:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
Climb Bio Releases New Clinical Data on Budoprutug
Climb Bio ( ($CLYM) ) has shared an announcement. Climb Bio, Inc. announced on ...
10-17 19:28
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Climb Bio, a biotech company, announced plans to present preclinical data on CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy (IgAN), and publish long-term clinical data on budoprutug, an anti-CD19 monoclonal antibody for primary membranous nephropathy (pMN), at the 2025 American Society of Nephrology Kidney Week. CLYM116 showed promising pharmacokinetic and pharmacodynamic properties in preclinical models, while budoprutug demonstr...
10-17 11:00
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
